UPDATE: Deutsche Bank Upgrades Affymetrix to Buy

Loading...
Loading...
Deutsche Bank has published a research report on Affymetrix
AFFX
and has upgraded the company from Hold to Buy as the risk/reward benefit is favorable. In the report, Deutsche Bank writes, "We are upgrading AFFX from Hold to Buy and are increasing our PT from $4.50 to $7.00 on the back of renewed strategic interest in the genomics market (Roche hostile bid for Illumina). We view the recent CEO change as catalyzing the R&D / commercial organizations, with the recent eBio deal accelerating the company's transition to downstream / applied markets. Our new PT is based on ~2.00x our FY12 revenue estimate of $322.0 million (adjusted for net debt)." Deutsche Bank has also raised the price target from $4.50 to $7 on Affymetrix, which is currently trading up $0.54 from yesterday's $4.75 closing price.
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsDeutsche Bank
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...